

REMARKS

Claims 1, 8, 11, 13, 14 were pending and rejected in the just prior, final Office Action. Claims 1, 11, 13, and 14 were rejected under the doctrine of “obviousness-type” double patenting in view of U.S. Patent No. 7,044,967. Claim 8 was objected to as depending from a rejected claim, but with allowable subject matter indicated.

Claim 1 has now been amended to include all of the elements previously present in it, along with a new element corresponding to the limitation previously found in claim 8. Claim 1 is now believed allowable as suggested in the just prior Office Action. The rest of the claims have now been cancelled from the application.

Conclusion

In view of the amendments and the remarks presented above, it is respectfully submitted that now Claim 1 is now in condition for allowance, and the Office’s reexamination, reconsideration and allowance of those claims and the application as a whole are now respectfully requested. The Examiner is further invited to contact Applicants’ undersigned attorney to resolve any remaining issues in order to expedite examination of the present application.

The Commissioner is hereby authorized to charge any required fees, including the fees required for the accompanying petition for a three month extension of time to respond to the outstanding Office Action, and any other fees due under the statute and the rules, including any petition for extension of time, or to credit any overpayment, to Deposit

Account No. 50-1225.

April 21, 2010



Michael L. Crapenhof
Registration No. 37,115
Edwards Lifesciences LLC
One Edwards Way
Irvine, California 92614
Telephone: (949) 250-2596
Facsimile: (949) 250-6850